2008•Tianjin yiyaoRequires access
Effects of Valsartan and Rosiglitazone on Expression of TGF-β1 in Focal Segmental Glomerulosclerosis Rats
Wenhong Wang
Open publisher page 0 citations
Abstract
Objective:To investigate the effects of valsartan and rosiglitazone on expression of TGF-β1 in kidney tissue of focal segmental glomerulosclerosis(FSGS)rats.Methods:Rat model of FSGS was constructed with one side nephrectomy and injection of adriamycin caudal-venously respectively.Rats were randomized to normal control group,valsartan-treated group,rosiglitazone-treated group,integrated treatment group and model group.Twenty-four hours urinary protein and blood biochemical indicators were measured at the 0,4th,6th and 8th week.The values of creatinine clearance(Ccr) was calculated.Renal pathological changes were evaluated at the 8th week.Expression of TGF-β1 was detected by immunohistochemical method,and the correlation between TGF-β1 expression and the pathological changes was analyzed.Results:Twenty-four hour urinary protein in each treatment group was lower than that in model group.The values of serum total protein(TP),albumin(ALB) increased significantly in each treatment group compared with that of model group.Meanwhile,the values of cholesterol decreased markedly,Ccr increased.The values of glomerular sclerotic index(SI) and glomerular extracellular matrix(ECM)/glomerular area(GA) were decreased significantly in each treatment group.The expression of TGF-β1 was lower in normal control group compared with that of model group.The expressions of TGF-β1 in each treatment group were decreased.Besides,there were differences between integrated treatment and other treatment group in 24 -hour urinary protein,renal pathological changes and expression of TGF-β1.Conclusion:The expression of TGF-β1 can reflect the progression of FSGS as the same as SI and ECM/GA.The integrated treatment of valsartan and rosiglitazone can be one of choices towards the treatment of FSGS except for hormone therapy.TGF-β1 may be an index of evaluating therapeutic effect.Both valsartan and rosiglitazone may be different targets to deal with FSGS.